|

A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder

RECRUITINGPhase 3Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Actively Recruiting
PhasePhase 3
SponsorOtsuka Pharmaceutical Development & Commercialization, Inc.
Started2026-10-08
Est. completion2029-05-26
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites

Summary

This is a global, Phase 3, multicenter, open-label extension trial designed to evaluate the long-term safety, tolerability and efficacy of SEP-363856 administered at doses of 50 milligrams (mg) or 75 mg per day in adult participants with generalized anxiety disorder (GAD) over a treatment period of 26 weeks.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Key Inclusion Criteria

1. Male or female participants at least 18 years of age at the time of informed consent
2. Completed one of the prior GAD Phase 3 studies involving SEP-363856 through Week 8 without discontinuation of trial intervention
3. Able to continue treatment without interruption, and is considered by investigator to potentially benefit from SEP-363856
4. Participant is willing and able to comply with study procedures and visit schedule
5. i) Females of childbearing potential: negative pregnancy test and agreement to use acceptable contraception ii) Males: agreement to follow protocol-defined contraception and reproductive restrictions

Key Exclusion Criteria

1. Diagnosis other than GAD that is the primary focus of treatment
2. Clinically significant psychiatric or medical condition that may interfere with study participation
3. Lifetime history of meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for, or was diagnosed during the prior study with, a psychiatric disorder that would compromise accurate assessment of safety and efficacy outcomes
4. Clinically significant abnormal laboratory values or ECG findings
5. Significant suicide risk
6. Substance use/positive drug screen
7. Use of prohibited medications/therapies
8. Known sensitivity to SEP-363856

Conditions2

AnxietyGeneralized Anxiety Disorder

Interventions1

Locations2 sites

Florida

1 site
Clinical Neuroscience Solutions, LLC
Otsuka Call Center844-687-8522Otsuka-ProfessionalServices@otsuka-us.com

New York

1 site
Basil Clinical
Jamaica, New York, 11413
Otsuka Call Center844-687-8522Otsuka-ProfessionalServices@otsuka-us.com

Find trials near these locations

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.